Klebsiella pneumoniae carbapenemases in enterobacteriaceae: History, evolution, and microbiology concerns

Pharmacotherapy

Volumn 32, Issue 5, 2012, Pages 399-407

  Rapp, Robert P ^a   Urban, Carl ^b,c  

^a University of Kentucky   (United States)

^b NEW YORK HOSPITAL QUEENS   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbapenemases; Carbapenems; Extended spectrum lactamases; Klebsiella pneumoniae carbapenemases; KPC; Polymyxin; Tigecycline

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AVIBACTAM; AZTREONAM; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CARBAPENEMASE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; COLISTIN; DORIPENEM; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TIGECYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER INFECTION; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIOLOGY; CLINICAL EFFECTIVENESS; COMMUNICABLE DISEASE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME ANALYSIS; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; TREATMENT DURATION; TREATMENT PLANNING; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; HUMANS; HYDROLYSIS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84864609500     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01035.x     Document Type: Article

References (82)

1. Kahan JS, Kahan FM, Goegelman R, Currie SA, Jackson M, Stapley EO, et al. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo) 1979;32(1):1-12.
2. Birnbaum J, Kahan FM, Kropp H, MacDonald JS. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985;78(6A):3-21.
3. Sefton AM. Mechanisms of antimicrobial resistance: Their clinical relevance in the new millennium. Drugs 2002;62(4):557-66.
4. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 1965;208 (5007):239-41.
5. Rolinson GN. The Garrod lecture. The influence of 6-Aminopenicillanic acid on antibiotic development. J Antimicrob Chemother 1988;22(1):5-4.
6. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997;24(Suppl 1):S19-45.
7. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264(5157):375-82.
8. El-Gamal MI, Oh CH. Current status of carbapenem antibiotics. Curr Top Med Chem 2010;10(18):1882-97.
9. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119(5):353-8.
10. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum betalactamases. Antimicrob Agents Chemother 1998;42(1):53-8.
11. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidimeresistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23(1):118-24.
12. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC Jr, et al. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34(11):2193-9.
13. Urban C, Rahal JJ. Klebsiella and extended spectrum beta-lactamases. Int J Antimicrob Agents 1997;8(1):37-43.
14. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extendedspectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000;6(9):460-3.
15. Ito H, Arakawa Y, Ohsuka S, Wacharotayankun R, Kato N, Ohta M. Plasmid-mediated dissemination of the metallo-betalactamase gene blaIMP among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995;39 (4):824-9.
16. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991;35(1):147-51.
17. Koh TH, Babini GS, Woodford N, Sng LH, Hall LM, Livermore DM. Carbapenem-hydrolysing IMP-1 beta-lactamase in Klebsiella pneumoniae from Singapore. Lancet 1999;353 (9170):2162.
18. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004;48(1):15-22.
19. Yan JJ, Ko WC, Wu JJ. Identification of a plasmid encoding SHV-12, TEM-1, and a variant of IMP-2 metallo-beta-lactamase, IMP-8, from a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45(8):2368-71.
20. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9(4):228-36.
21. Geddes A. 80th Anniversary of the discovery of penicillin An appreciation of Sir Alexander Fleming. Int J Antimicrob Agents 2008;32(5):373.
22. Chain E, Florey HW, Adelaide MB, Gardner AD, Heatley NG, Jennings MA, et al. Penicillin as a chemotherapeutic agent. 1940. Clin Orthop Relat Res 1993;295:3-7.
23. Ligon BL. Penicillin: Its discovery and early development. Semin Pediatr Infect Dis 2004;15(1):52-7.
24. Fleming A. In-vitro tests of penicillin potency. Lancet 1942;239(6199):732-3.
25. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42(7):1762-70.
26. Nathwani D, Wood MJ. Penicillins. A current review of their clinical pharmacology and therapeutic use. Drugs 1993;45 (6):866-94.
27. Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 2008;14(Suppl 1):134-43.
28. Jacoby G, Bush K. b-Lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes. Available online from URL: Http://www.lahey.org/Studies/. Accessed August 7, 2011.
29. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985;28(2):302-7.
30. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14 (4):933-51.
31. Bush K, Jacoby GA. Updated functional classification of betalactamases. Antimicrob Agents Chemother 2010;54(3):969-76.
32. Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 1980;289(1036):321-31.
33. Queenan AM, Bush K. Carbapenemases: The versatile beta-lactamases. Clin Microbiol Rev 2007;20(3):440-58.
34. Babic M, Hujer AM, Bonomo RA. What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist Updat 2006;9(3):142-56.
35. Pitout JD. Multiresistant Enterobacteriaceae: New threat of an old problem. Expert Rev Anti Infect Ther 2008;6(5):657-69.
36. Walther-Rasmussen J, Hoiby N. Class A carbapenemases. J Antimicrob Chemother 2007;60(3):470-82.
37. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing b-Actamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2008;52 (2):809.
38. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis 2006;56(4):367-72.
39. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob Agents Chemother 2010;54(2):890-7.
40. Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007;45(8):2723-5.
41. Nordmann P, Mariotte S, Naas T, Labia R, Nicolas MH. Biochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrob Agents Chemother 1993;37 (5):939-46.
42. Tenover FC, Kalsi RK, Williams PP, Carey RB, Stocker S, Lonsway D, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006;12(8):1209-13.
43. Zhang R, Yang L, Cai JC, Zhou HW, Chen GX. High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression. J Med Microbiol 2008;3:332-7.
44. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 19th Informational Supplement CLSI document M100-S19 ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
45. McGettigan SE, Andreacchio K, Edelstein PH. Specificity of ertapenem susceptibility screening for detection of Klebsiella pneumoniae carbapenemases. J Clin Microbiol 2009;47 (3):785-6.
46. Landman D, Urban C, Backer M, Kelly P, Shah N, Babu E, et al. Susceptibility profiles, molecular epidemiology, and detection of KPC-producing Escherichia coli isolates from the New York City vicinity. J Clin Microbiol 2010;48(12):4604-7.
47. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2001;7(2):88-91.
48. Endimiani A, Depasquale JM, Forero S, Perez F, Hujer AM, Roberts-Pollack D, et al. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-Term acute care hospital: A new challenge to our healthcare system. J Antimicrob Chemother 2009;64(5):1102-10.
49. Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Papahatzaki H, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 2009;58(3):213-9.
50. Mathers AJ, Cox HL, Bonatti H, Kitchel B, Brassinga AK, Wispelwey B, et al. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009;11(3):257-65.
51. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29(12):1099-106.
52. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extendedspectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011;86(3):250-9.
53. Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 2006;43(3):e26-8.
54. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 2009;64 (2):233-5.
55. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: A new threat to our antibiotic armamentarium. Arch Intern Med 2005;165(12):1430-5.
56. Zahar JR, Lortholary O, Martin C, Potel G, Plesiat P, Nordmann P. Addressing the challenge of extended-spectrum betalactamases. Curr Opin Investig Drugs 2009;10(2):172-80.
57. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenemresistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51(8):3026-9.
58. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extendedspectrum beta-lactamases. Clin Infect Dis 2004;39(1):31-7.
59. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Comparison of the activity of a human simulated, highdose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2010;54(2):804-10.
60. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;43(10):1116-23.
61. Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother 2010;54(1):565-9.
62. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: What are the treatment options? Drugs 2009;69 (14):1879-901.
63. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: Molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56(1):128-32.
64. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broadspectrum antimicrobials tested against serine carbapenemaseand metallo-beta-lactamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52(2):570-3.
65. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: Risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009;30(7):666-71.
66. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: A report of 2 cases and a brief review of the literature. Clin Infect Dis 2009;49 (2):271-4.
67. Keeney D, Ruzin A, McAleese F, Murphy E, Bradford PA. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008;61(1):46-53.
68. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: A systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008;62 (5):895-904.
69. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007;27(7):1052-7.
70. Walsh TR. Clinically significant carbapenemases: An update. Curr Opin Infect Dis 2008;21(4):367-71.
71. Falagas ME, Rafailidis PI. Re-emergence of colistin in today's world of multidrug-resistant organisms: Personal perspectives. Expert Opin Investig Drugs 2008;17(7):973-81.
72. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6(9):589-601.
73. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J Antimicrob Chemother 2007;60(6):1206-15.
74. Weinstein L, Doan TL, Smith MA. Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports. Am J Health Syst Pharm 2009;66(4):345-7.
75. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant gram nosocomial pneumonia: A case series. Respir Med 2009;103(5):707-13.
76. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: A review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009;34(1):8-e1.
77. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of AVIBACTAM in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009;53(8):3599-601.
78. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. AVIBACTAM combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother 2008;62(5):1053-6.
79. Shahid M, Sobia F, Singh A, Malik A, Khan HM, Jonas D, et al. Beta-lactams and beta-lactamase-inhibitors in current-or potential-clinical practice: A comprehensive update. Crit Rev Microbiol 2009;35(2):81-108.
80. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, et al. In vitro activity of the beta-lactamase inhibitor AVIBACTAM against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009;64(2):326-9.
81. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase- producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55(6):3002-4.
82. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010;54(6):2732-4.